PT027 (albuterol/budesonide) is a potential first-in-class inhaled, fixed-dose combination of the short-acting beta2-agonist albuterol and budesonide, an inhaled corticosteroid.
Breztri will be the first inhaler in AstraZeneca’s portfolio to use ... It is a fixed-dose combination of a corticosteroid ...
Three major pharmaceutical companies—AstraZeneca ... (glycopyrrolate and formoterol fumarate) inhalation aerosol - Breztri ...
Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ ... acting beta2-agonist (SABA), and budesonide (an anti-inflammatory inhaled corticosteroid or ICS) – Airsupra ...
Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...